Send us Feedback

Sanofi-Aventis SA (SNY)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

SNY » Topics » Alliances

This excerpt taken from the SNY 20-F filed Mar 4, 2009.

Alliances

 

We have two principal alliances through which three of our main products are marketed. The first, with Bristol-Myers Squibb, governs the development and marketing of Plavix® and Aprovel®/CoAprovel®. The second, with Procter & Gamble Pharmaceuticals, governs the development and commercialization of Actonel®. We also have a marketing agreement with Teva Pharmaceutical Industries regarding Copaxone®.

 

The financial impact of our principal alliances on our financial condition or income is significant and is described under “Item 5. Operating and Financial Review and Prospects — Financial Presentation of Alliances.”

 

This excerpt taken from the SNY 20-F filed Mar 7, 2008.

Alliances

 

We have three major alliances through which four of our top 15 products are marketed. The first, with Bristol-Myers Squibb, governs the development and marketing of Plavix® and Aprovel®. The second, with Procter & Gamble Pharmaceuticals, governs the development and commercialization of Actonel®. The third is a marketing agreement with Teva Pharmaceutical Industries regarding Copaxone®.

 

The financial impact of our principal alliances on our financial condition or results of operations is significant and is described under “Item 5. Operating and Financial Review and Prospects — Financial Presentation of Alliances.”

 

This excerpt taken from the SNY 20-F filed Apr 3, 2007.

Alliances

 

We have three major alliances through which four of our top 15 products are marketed. The first, with Bristol-Myers Squibb, governs the development and marketing of Plavix® and Aprovel®. The second, with Procter & Gamble Pharmaceuticals, governs the development and commercialization of Actonel®. The third is a marketing agreement with Teva Pharmaceuticals regarding Copaxone®.

 

The financial impact of our principal alliances on our financial condition or results of operations is significant and is described under “Item 5. Operating and Financial Review and Prospects — Financial Presentation of Alliances.”

 

55

Table of Contents
This excerpt taken from the SNY 20-F filed Mar 31, 2006.

Alliances

 

In 2005, we had three major alliances through which four of our top 15 products were marketed. The first, with Bristol-Myers Squibb, or BMS, governs the development and marketing of Plavix® and Aprovel®. The second, with Procter & Gamble Pharmaceuticals, or P&G, governs the development and commercialization of Actonel®. The third is a marketing agreement with Teva Pharmaceuticals regarding Copaxone®.

 

The financial impact of our principal alliances on our financial condition or results of operations is significant and is described in detail under “Item 5. Operating and Financial Review and Prospects — Overview — Financial Presentation of Alliances”.

 

This excerpt taken from the SNY 20-F filed Apr 11, 2005.

Alliances

 

In 2004, we had three major alliances through which 4 of our top 15 products were marketed. The first, with Bristol-Myers Squibb, or BMS, governs the development and marketing of Plavix® and Aprovel®. The second, with Procter & Gamble Pharmaceuticals, or P&G, governs the development and commercialization of Actonel®. The third is a marketing agreement with Teva regarding Copaxone®.

 

The financial impact of our principal alliances on our financial condition or results of operations is significant and is described in detail under “Item 5. Operating and Financial Review and Prospects – Overview – Financial Presentation of Alliances”.

 

EXCERPTS ON THIS PAGE:

20-F
Mar 4, 2009
20-F
Mar 7, 2008
20-F
Apr 3, 2007
20-F
Mar 31, 2006
20-F
Apr 11, 2005

RELATED TOPICS for SNY:

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki